Meeting
2023 ASCO Annual Meeting
A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors.
Authors
Sarina A. Piha-Paul
The University of Texas MD Anderson Cancer Center, Houston, TX
Sarina A. Piha-Paul , Seema Nagpal , Amy M. Weise , Fadi S. Braiteh , Chen Chen , Charles Qing Huang , William Liu , Yong Hu , Zane Yang , Katy K. Tsai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04190628
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3098)
DOI
10.1200/JCO.2023.41.16_suppl.3098
Abstract #
3098
Poster Bd #
296
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase I, single-institution open label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.
First Author: S. R. Ahmed
Poster
2021 ASCO Annual Meeting
Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.
First Author: Vivek Subbiah
Poster
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Ryan J. Sullivan